ArticleJournal of hazardous materials2025
Health impacts of asphalt emissions: Examining neurological risks and the need for long-term exposure mitigation.
Article in Journal of hazardous materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Road Performance, VOCs Emission Behavior, and Emission Mechanism of Rubber Powder/SBS-Modified Asphalt.Materials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Asphalt, widely used in infrastructure, emits complex chemical mixtures throughout its service life, posing significant risks to human health and the environment. This expanded understanding extends the concern from a construction-related hazard to a broader public health issue, especially affecting vulnerable populations like children who play on blacktop surfaces. Despite increased awareness, the specific mechanisms behind asphalt emissions, their impact on asphalt deterioration, and their effects on the human nervous system remain poorly understood. Our study addresses these knowledge gaps by examining the long-term health effects of asphalt emissions, focusing on neurological impacts. We investigate how environmental stressors and asphalt's chemical composition influence emission types and severity, using a combination of in vitro experiments, Drosophila melanogaster models, and advanced computational analyses. FTIR analysis reveals that as asphalt ages, emissions evolve from aliphatic to aromatic compounds, increasing toxicity. Our results demonstrate significant neurological damage from asphalt emissions, with effects worsening with age and being more pronounced in females, as shown in the Drosophila model, emphasizing the need for gender-specific health risk research. In vitro studies using 3T3L1 cells show that VOC exposure disrupts lipid droplet formation and metabolism, processes linked to neurodegenerative disorders. To mitigate emissions, our novel approach introduces wood-based biochar as a functional carbon to enhance intermolecular interactions within asphalt. GC-MS analysis indicates that biochar reduces VOC emissions by up to 76 %, while molecular dynamics (MD) simulations highlight biochar's effectiveness in hindering free-radical diffusion. Density functional theory (DFT) calculations confirm biochar's role, with adsorption energies of -20.4 kcal/mol, demonstrating strong and stable interactions that decelerate oxidative aging and mass loss. These findings offer a comprehensive understanding of emission mechanisms and propose a sustainable strategy to enhance asphalt durability while reducing environmental and health risks. This in turn provides evidence-based recommendations for the asphalt industry, emphasizing proactive measures toward long-term exposure mitigation. SYNOPSIS: Asphalt emits chemicals throughout its service life, posing neurological risks, especially to vulnerable groups, and needs emission mitigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.